Jefferies analyst Michael Yee maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $350.00. The company’s ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a ...

Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen ...

UBS raised the firm’s price target on Amgen (AMGN) to $319 from $315 and keeps a Neutral rating on the shares. The firm is expecting an in-line ...

Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...

April 11, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA ® (tarlatamab-dlle) as a treatment for patients with ...

There’s a whole lot to admire in this project. The swing-out transparent OLED display is super slick, the electronics are housed on a single PCB, the back half of the grip is in fact a portable ...